---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-077646"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:00:19.946413+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Larimar Therapeutics prices 20M share public offering at $5.00 per share; underwriters exercise over-allotment

## Summary
- Offering of 20,000,000 shares plus 3,000,000 over-allotment shares at $5.00 per share.
- Net proceeds after underwriting discounts and expenses expected to be approx. $107.6M.
- Underwriters include J.P. Morgan, Guggenheim, LifeSci Capital, William Blair, and others.
- Offering expected to close on February 27, 2026.

## SEC filing metadata
- accession: 0001193125-26-077646
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000119312526077646/0001193125-26-077646-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000119312526077646/d120172d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-077646
- JSON: https://secwatch.observer/filing/0001193125-26-077646.json
- Plain text: https://secwatch.observer/filing/0001193125-26-077646.txt

## Key facts
- Material Agreements
  Larimar Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Guggenheim Securities, LLC valued at 20,000,000 shares at $5.00 per share, option for additional 3,000,000 shares exercised, net proceeds (effective 2026-02-25).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: J.P. Morgan Securities LLC and Guggenheim Securities, LLC
  - Value: 20,000,000 shares at $5.00 per share, option for additional 3,000,000 shares exercised, net proceeds
  - Effective: 2026-02-25
  source text: On February 25, 2026, Larimar Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “ Underwriters ”), relating to the issuance and sale of an aggregate of 20,000,000 shares (the “ Firm Shares ”) of common stock, par value $0.001 per share (the “ Common Stock ”), of the Company at a public offering price of $5.00 per share (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374690/000119312526077646/0001193125-26-077646-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.